Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Locoregional Recurrence
Hormone Receptor-positive Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Ribociclib
DRUG: Fulvestrant
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Exemestane

Sponsor

Oana Danciu

Collaborators

[object Object]